Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Decreases By 26.8%

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a large decline in short interest during the month of January. As of January 30th, there was short interest totaling 250,987 shares, a decline of 26.8% from the January 15th total of 342,721 shares. Approximately 1.2% of the shares of the stock are short sold. Based on an average daily volume of 51,369 shares, the short-interest ratio is presently 4.9 days. Based on an average daily volume of 51,369 shares, the short-interest ratio is presently 4.9 days. Approximately 1.2% of the shares of the stock are short sold.

ABVC BioPharma Stock Performance

Shares of ABVC remained flat at $1.67 during trading on Friday. 22,229 shares of the company’s stock were exchanged, compared to its average volume of 55,663. The business’s fifty day moving average is $2.08 and its 200-day moving average is $2.60. ABVC BioPharma has a 1-year low of $0.41 and a 1-year high of $5.48. The firm has a market cap of $42.46 million, a PE ratio of -8.35 and a beta of 0.21.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ABVC BioPharma in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On ABVC BioPharma

A number of institutional investors have recently modified their holdings of ABVC. Geode Capital Management LLC lifted its position in shares of ABVC BioPharma by 7.7% during the fourth quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock worth $431,000 after purchasing an additional 14,553 shares in the last quarter. Millennium Management LLC purchased a new stake in ABVC BioPharma during the 3rd quarter worth approximately $60,000. Finally, Citadel Advisors LLC acquired a new stake in ABVC BioPharma during the 3rd quarter worth approximately $48,000. 11.38% of the stock is owned by institutional investors and hedge funds.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.